Omega Therapeutics (OMGA) Stock Forecast, Price Target & Predictions
OMGA Stock Forecast
Omega Therapeutics stock forecast is as follows: an average price target of $9.00 (represents a 1059.79% upside from OMGA’s last price of $0.78) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
OMGA Price Target
The average price target for Omega Therapeutics (OMGA) is $9.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $7.00. This represents a potential 1059.79% upside from OMGA's last price of $0.78.
OMGA Analyst Ratings
According to 1 Wall Street analysts, Omega Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for OMGA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Omega Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 03, 2024 | Edward Tenthoff | Piper Sandler | $9.00 | $3.01 | 199.00% | 1059.79% |
| Apr 01, 2024 | Keay Nakae | Loop Capital Markets | $7.00 | $3.65 | 91.78% | 802.06% |
| Dec 08, 2022 | - | H.C. Wainwright | $11.00 | $6.30 | 74.60% | 1317.53% |
The latest Omega Therapeutics stock forecast, released on Apr 03, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $9.00, which represents a 199.00% increase from the stock price at the time of the forecast ($3.01), and a 1059.79% increase from OMGA last price ($0.78).
Omega Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $8.00 |
| Last Closing Price | $0.78 | $0.78 | $0.78 |
| Upside/Downside | -100.00% | -100.00% | 930.93% |
In the current month, the average price target of Omega Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Omega Therapeutics's last price of $0.78. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 15, 2024 | Raymond James | Underperform | Underperform | Hold |
| Jun 18, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Jun 18, 2024 | Raymond James | Buy | Buy | Hold |
| Jun 18, 2024 | Raymond James | - | Outperform | Initialise |
| May 07, 2024 | Chardan Capital | Underperform | Underperform | Hold |
| May 07, 2024 | Piper Sandler | Buy | Buy | Hold |
| Apr 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 01, 2024 | Chardan Capital | Buy | Buy | Hold |
Omega Therapeutics's last stock rating was published by Wedbush on Aug 15, 2024. The company gave OMGA a "Buy" rating, the same as its previous rate.
Omega Therapeutics Financial Forecast
Omega Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $831.00K | $759.00K | $516.00K | $735.00K | $595.00K | $476.00K | $268.00K |
| Avg Forecast | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $700.00K | $956.14K | $1.16M | $450.00K | $442.86K | $378.57K | $314.29K | $257.50K | $101.20K | $51.50K | $338.53K |
| High Forecast | $1.18M | $1.18M | $1.18M | $1.00M | $1.34M | $1.18M | $956.21K | $1.16M | $483.87K | $743.56K | $635.63K | $527.69K | $432.35K | $101.20K | $51.50K | $406.23K |
| Low Forecast | $388.89K | $388.89K | $388.89K | $504.24K | $280.00K | $388.89K | $956.07K | $1.16M | $411.29K | $246.03K | $210.32K | $174.60K | $143.06K | $101.20K | $51.50K | $270.82K |
| # Analysts | 3 | 3 | 3 | 5 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.88% | 2.00% | 1.64% | 2.85% | 5.88% | 9.24% | 0.79% |
Omega Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $450.00K, with a low forecast of $411.29K, and a high forecast of $483.87K. OMGA's average Quarter revenue forecast represents a -45.85% decrease compared to the company's last Quarter revenue of $831.00K (Sep 23).
Omega Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-22.90M | $-30.84M | $-25.82M | $-30.97M | $-25.59M | $-25.45M | $-19.63M |
| Avg Forecast | $-140.00K | $-140.00K | $-140.00K | $-140.00K | $-140.00K | $-140.00K | $-191.23K | $-232.86K | $-90.00K | $-88.57K | $-75.71K | $-62.86K | $-51.50K | $-20.24K | $-10.30K | $-24.80M |
| High Forecast | $-77.78K | $-77.78K | $-77.78K | $-100.85K | $-56.00K | $-77.78K | $-191.21K | $-232.83K | $-82.26K | $-49.21K | $-42.06K | $-34.92K | $-28.61K | $-20.24K | $-10.30K | $-19.84M |
| Low Forecast | $-235.06K | $-235.06K | $-235.06K | $-200.51K | $-267.68K | $-235.06K | $-191.24K | $-232.88K | $-96.77K | $-148.71K | $-127.12K | $-105.54K | $-86.47K | $-20.24K | $-10.30K | $-29.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | 258.58% | 407.32% | 410.74% | 601.31% | 1264.44% | 2470.82% | 0.79% |
undefined analysts predict OMGA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Omega Therapeutics's previous annual EBITDA (undefined) of $NaN.
Omega Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
| Net Income | - | - | - | - | - | - | - | - | - | $-22.25M | $-29.69M | $-24.06M | $-30.68M | $-25.61M | $-25.97M | $-20.37M |
| Avg Forecast | $-14.52M | $-14.34M | $-15.07M | $-14.16M | $-13.60M | $-14.61M | $-20.15M | $-18.36M | $-24.73M | $-29.15M | $-27.42M | $-32.38M | $-34.30M | $-32.68M | $-31.16M | $-25.47M |
| High Forecast | $-6.13M | $-6.05M | $-6.36M | $-9.23M | $-10.65M | $-6.17M | $-8.51M | $-7.75M | $-24.19M | $-12.31M | $-11.58M | $-13.67M | $-14.48M | $-32.68M | $-31.16M | $-20.38M |
| Low Forecast | $-27.34M | $-27.00M | $-28.38M | $-17.23M | $-16.56M | $-27.52M | $-37.93M | $-34.56M | $-25.80M | $-54.88M | $-51.62M | $-60.96M | $-64.58M | $-32.68M | $-31.16M | $-30.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.76% | 1.08% | 0.74% | 0.89% | 0.78% | 0.83% | 0.80% |
Omega Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. OMGA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Omega Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
| SG&A | - | - | - | - | - | - | - | - | - | $7.87M | $6.21M | $5.95M | $5.36M | $5.20M | $6.20M | $5.41M |
| Avg Forecast | $19.08M | $19.08M | $19.08M | $19.08M | $19.08M | $19.08M | $26.06M | $31.74M | $12.27M | $12.07M | $10.32M | $8.57M | $7.02M | $2.71M | $1.38M | $9.08M |
| High Forecast | $32.04M | $32.04M | $32.04M | $27.33M | $36.48M | $32.04M | $26.06M | $31.74M | $13.19M | $20.27M | $17.33M | $14.38M | $11.78M | $2.71M | $1.38M | $10.90M |
| Low Forecast | $10.60M | $10.60M | $10.60M | $13.74M | $7.63M | $10.60M | $26.06M | $31.73M | $11.21M | $6.71M | $5.73M | $4.76M | $3.90M | $2.71M | $1.38M | $7.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.65% | 0.60% | 0.70% | 0.76% | 1.92% | 4.49% | 0.60% |
Omega Therapeutics's average Quarter SG&A projection for Dec 23 is $12.27M, based on 3 Wall Street analysts, with a range of $11.21M to $13.19M. The forecast indicates a 55.88% rise compared to OMGA last annual SG&A of $7.87M (Sep 23).
Omega Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 5 | 5 | 4 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.40 | $-0.54 | $-0.48 | $-0.64 | $-0.54 | $-0.54 | $-0.43 |
| Avg Forecast | $-0.26 | $-0.26 | $-0.27 | $-0.26 | $-0.25 | $-0.27 | $-0.37 | $-0.33 | $-0.45 | $-0.53 | $-0.50 | $-0.59 | $-0.62 | $-0.59 | $-0.56 | $-0.57 |
| High Forecast | $-0.11 | $-0.11 | $-0.12 | $-0.17 | $-0.19 | $-0.11 | $-0.15 | $-0.14 | $-0.44 | $-0.22 | $-0.21 | $-0.25 | $-0.26 | $-0.59 | $-0.56 | $-0.57 |
| Low Forecast | $-0.50 | $-0.49 | $-0.51 | $-0.31 | $-0.30 | $-0.50 | $-0.69 | $-0.63 | $-0.47 | $-1.00 | $-0.94 | $-1.11 | $-1.17 | $-0.59 | $-0.56 | $-0.57 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.76% | 1.09% | 0.82% | 1.03% | 0.91% | 0.96% | 0.76% |
According to undefined Wall Street analysts, Omega Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OMGA previous annual EPS of $NaN (undefined).
Omega Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OMGA | Omega Therapeutics | $0.78 | $9.00 | 1053.85% | Buy |
| PMVP | PMV Pharmaceuticals | $1.61 | $18.00 | 1018.01% | Buy |
| PEPG | PepGen | $4.32 | $29.50 | 582.87% | Buy |
| AVTE | Aerovate Therapeutics | $2.61 | $13.00 | 398.08% | Hold |
| CMPX | Compass Therapeutics | $1.38 | $5.00 | 262.32% | Buy |
| OLMA | Olema Pharmaceuticals | $7.87 | $28.50 | 262.13% | Buy |
| LRMR | Larimar Therapeutics | $6.13 | $20.33 | 231.65% | Buy |
| GPCR | Structure Therapeutics | $30.10 | $92.40 | 206.98% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| MLYS | Mineralys Therapeutics | $11.87 | $30.00 | 152.74% | Buy |
| CVKD | Cadrenal Therapeutics | $14.01 | $32.00 | 128.41% | Buy |
| PHVS | Pharvaris | $21.04 | $39.67 | 88.55% | Buy |
| ELVN | Enliven Therapeutics | $25.41 | $39.50 | 55.45% | Buy |
| MLTX | MoonLake Immunotherapeutics | $51.86 | $79.33 | 52.97% | Buy |
| CNTA | Centessa Pharmaceuticals | $18.19 | $23.25 | 27.82% | Buy |